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Efficacy and Safety of Abatacept in Lupus Nephritis
A Twelve-Month, Randomized, Double-Blind Study
Richard Furie,1 Kathy Nicholls,2 Tien-Tsai Cheng,3 Frederic Houssiau,4 Ruben Burgos-Vargas,5
Shun-Le Chen,6 Jan L. Hillson,7 Stephanie Meadows-Shropshire,7
Michael Kinaszczuk,7 and Joan T. Merrill8
Objective. To compare the efficacy and safety of
intravenous (IV) abatacept, a selective T cell costimulation modulator, versus placebo for the treatment of active class III or IV lupus nephritis, when used on a background of mycophenolate mofetil and glucocorticoids.
Methods. This was a 12-month, randomized,
phase II/III, multicenter, international, double-blind
study. A total of 298 patients were treated in 1 of 3 IV

treatment arms: placebo, abatacept at the standard
weight-tiered dose (approximating 10 mg/kg), or abatacept at 30 mg/kg for 3 months, followed by the standard
weight-tiered dose (abatacept 30/10). The primary end
point, time to confirmed complete response, was a
composite measure that required maintenance of glomerular filtration rate, minimal proteinuria, and inactive urinary sediment over the 52-week treatment period.
Results. There were no differences among treatment arms in the time to confirmed complete response
or in the proportion of subjects with confirmed complete
response following 52 weeks of treatment. Treatment
with abatacept was associated with greater improvements from baseline in anti–double-stranded DNA antibody, C3, and C4 levels. Among 122 patients with
nephrotic-range proteinuria, treatment with abatacept
resulted in an ⬃20–30% greater reduction in mean
urinary protein-to-creatinine ratio compared with placebo. Abatacept was well tolerated; rates of deaths,
serious adverse events, and serious infections were
similar across treatment arms. Gastroenteritis and herpes zoster occurred more frequently with abatacept
treatment.
Conclusion. Although the primary end point was
not met, abatacept showed evidence of biologic activity
and was well tolerated in patients with active class III or
IV lupus nephritis.
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Lupus nephritis (LN) is characterized by the
activation and persistence of autoreactive T and B cells
and the presence of potentially pathogenic autoantibodies (1). Abatacept is a fusion protein comprising
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CTLA-4 linked to the Fc portion of IgG1 (2). It selectively modulates the CD28–CD80/86 signaling pathway,
thereby inhibiting costimulatory events, including T cell
activation (3,4). Inhibition of costimulation is effective in
murine models of LN (5–7). Abatacept is currently
approved for the treatment of rheumatoid arthritis (RA)
and juvenile inflammatory arthritis, and is being explored for the treatment of other autoimmune diseases
(2,8,9).
Results of a phase II study (ClinicalTrials.gov
identifier NCT00119678) of abatacept for the treatment
of patients with systemic lupus erythematosus (SLE)
presenting with arthritis, serositis, or discoid lesions
were previously reported (9). Patients (n ⫽ 175) were
randomized 2:1 to receive intravenous (IV) abatacept
(⬃10 mg/kg) or placebo, in addition to prednisone (30
mg/day or equivalent for 4 weeks, with subsequent
dosage modifications at the discretion of the investigator) and stable background immunosuppressants. The
primary efficacy end point, i.e., the proportion of patients without one or more moderate or severe flares
(British Isles Lupus Assessment Group [BILAG] B
flares or BILAG A flares, respectively) (10) during the
12-month treatment period, was not met. However, post
hoc analyses suggested that abatacept treatment was
associated with fewer major BILAG A flares, as well as
improvements in exploratory quality-of-life measures
(Short Form-36 [SF-36] health survey [11], sleep problems, fatigue) and biomarker levels (reductions in mean
serum anti–double-stranded [anti-dsDNA] antibody levels from baseline) (9).
The present study (ClinicalTrials.gov identifier
NCT00430677) evaluated the efficacy and safety of
52-week treatment with IV abatacept compared with
placebo, on a background of mycophenolate mofetil
(MMF) and glucocorticoids in patients with SLE and
active class III or IV LN (12).
PATIENTS AND METHODS
Study design. This 12-month, international, multicenter, randomized, phase II/III, double-blind, placebocontrolled, parallel-group study was conducted at 85 sites
worldwide, including 17 in North America, 13 in Europe, 17 in
South America, 20 in Asia, and 18 in the rest of the world
(Australia, India, South Africa, and Turkey). To be eligible for
enrollment, patients had to be age ⱖ18 years, have met
classification criteria for SLE as defined by the American
College of Rheumatology (ACR) (13), and have active class III
or IV glomerulonephritis (with or without class V) as defined
by the 2003 International Society of Nephrology/Renal Pathology Society criteria (14), excluding class III[C], IV-S[C], or
IV-G[C], or the World Health Organization 1982 classification

criteria (15), excluding class IIIc or IVd, demonstrated on
renal biopsy ⱕ12 months prior to enrollment. For biopsies
performed ⬎3 months prior to enrollment, complement C3 or
C4 levels below the lower limit of normal (LLN) or elevated
anti-dsDNA antibody titers at the time of screening were
further requirements for eligibility, as were a urinary proteinto-creatinine ratio of ⱖ0.44 mg/mg (50 mg/mmole) at the time
of screening, and active urinary sediment (⬎5 red blood cells
[RBCs] or ⬎8 white blood cells [WBCs] per high-power field
[hpf] or cylinduria) at the time of screening or during the
current flare.
Patients were excluded if there was evidence of severe,
rapidly advancing renal insufficiency (i.e., an increase in serum
creatinine levels of ⱖ1 mg/dl within 1 month prior to screening, or a serum creatinine level of ⬎3 mg/dl), or if there was
evidence of severe, unstable, and/or progressive central nervous system lupus. Use of immunosuppressive or immunomodulatory agents during the study was prohibited, except for
antimalarial agents and protocol-defined MMF and glucocorticoids.
Treatment protocol. Patients were randomized 1:1:1 to
one of the following IV infusion treatment regimens: abatacept
30/10 mg/kg (abatacept 30/10), abatacept 10/10 mg/kg (abatacept 10/10), or placebo. Patients assigned to the abatacept
30/10 regimen received abatacept 30 mg/kg on days 1, 15, 29,
and 57, followed by abatacept approximating 10 mg/kg (weight
tiered: 500 mg for patients weighing ⬍60 kg, 750 mg for
patients 60–100 kg, 1,000 mg for patients ⬎100 kg) on days 85,
113, 141, 169, 197, 225, 253, 281, 309, and 337. In the abatacept
10/10 group, patients received weight-tiered doses of abatacept
approximating 10 mg/kg on all infusion days. Placebo consisted
of dextrose 5% in water or normal saline. In all treatment
groups, patients received MMF and prednisone or prednisone
equivalent, with MMF initiated at dosages based on race and
prior treatment, followed by adjustment or taper in accordance
with protocol recommendations and investigator discretion
(see Supplementary Tables 1 and 2, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38260/abstract). Randomization was stratified by
prior treatment: 1) naive (not currently receiving MMF and/or
glucocorticoid treatment at the screening visit), 2) recent
treatment (ⱕ3 months of therapy with MMF and/or glucocorticoids for current episode of LN), or 3) inadequate response
(⬎3 months of therapy with MMF and/or glucocorticoids with
persisting evidence of active LN).
Treatment with antiproteinuric agents (e.g., angiotensin II receptor blockers or angiotensin-converting enzyme
inhibitors) could not be initiated after randomization, but
could be continued at stable, pretreatment dosages. The
addition of other antihypertensive medications, such as
calcium-channel blockers, to improve blood pressure control
was permitted. Antimalarial medications and nonsteroidal
antiinflammatory drugs were allowed, providing the dosage
was stable throughout the study.
Primary and secondary study end points. The primary
efficacy end point during the 12-month double-blind treatment
period was the time to confirmed complete response. Complete response was defined as fulfillment of the following
criteria: 1) Modification of Diet in Renal Disease (MDRD)
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estimated glomerular filtration rate (eGFR) ⱖ90%* of screening level if normal at screening visit, or eGFR ⱖ90%* of
6-month, pre-flare value if abnormal at screening, 2) urinary
protein-to-creatinine ratio ⬍0.26 gm/gm (30 mg/mmole), and
3) inactive urinary sediment (RBCs and WBCs per hpf within
normal limits of central laboratory assessments; no RBC or
WBC casts). In order to meet criteria for confirmed complete
response, all complete response criteria had to be met once
again, 4 weeks after they were initially achieved. The complete
response criteria were adopted from the ACR response criteria
published at the time of the trial (21), which required a urinary
protein-to-creatinine ratio of ⬍0.20 gm/gm, inactive urine
sediment, and normal eGFR or a decline of ⬍25% from
baseline. The present study requirement of ⱕ10% decline
reflected health authority concerns about the applicability of
ACR criteria to a global population.
The key secondary efficacy end point was the proportion of patients in whom confirmed complete response had
been achieved at week 52 (complete response on days 337 and
365). Additional secondary efficacy end points included the
time to partial response (designated as renal improvement)
and the proportion of patients with renal improvement. To be
considered as having achieved renal improvement, patients
were required to have an inactive urinary sediment regardless
of the screening value. Furthermore, patients with abnormal
proteinuria at screening must have had a ⱖ50% improvement
in the urinary protein-to-creatinine ratio from the screening
visit value. Finally, patients with normal MDRD eGFR or with
mild renal insufficiency (eGFR 60–89 ml/minute/1.73 m2) at
screening must have had an eGFR of ⱖ90% of the screening
visit value, and patients with moderate-to-severe renal insufficiency (eGFR 15–59 ml/minute/1.73 m2) must have had a
ⱖ50% improvement in eGFR based on the screening visit
value, or an eGFR of ⱖ90% of the screening or 6-month
pre-flare value.
Other secondary efficacy end points were as follows:
durability of complete response (the median number of
months a complete response was maintained during the
double-blind treatment period), mean change from baseline in
renal function over time, mean change from baseline in the
Systemic Lupus International Collaborative Clinics/ACR
Damage Index (SDI) (22) up to week 52, mean change from
baseline in the patient’s health-related quality of life at each
scheduled assessment (measured using the physical and mental
component summary scores and each individual component
score of the SF-36 questionnaire), and changes from baseline
score at each scheduled assessment in the Fatigue Visual
Analog Scale (VAS) and total Krupp Fatigue Severity Scale
(FSS) (23).
Exploratory study end points. Prior to database lock
and unblinding, a modified set of renal outcome criteria, which
incorporated different proteinuria thresholds and serum
*The original protocol contained a syntax error in the definition of eGFR that was used to determine complete response and renal
improvement. This error, which considered patients with ⬎10% improvement in eGFR as having not met the end point, was reflected in
previous presentations of data (12,16–20) but has been corrected in the
present report. The error impacts the number of patients reported as
having achieved complete response and renal improvement, but does
not impact interpretations of treatment effect.
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creatinine–based renal measures and allowed for the assessment of complete and/or partial renal responses, was agreed
upon; these modified renal outcomes were evaluated as exploratory end points. The modified renal response criterion,
incorporated to evaluate renal response as determined using a
less stringent definition, was defined as follows: serum creatinine ⱕ125% of baseline level and improvement in urinary
protein-to-creatinine ratio (⬍50% of baseline and ⬍3.0 gm/gm
[339 mg/mmole] if nephrotic [urinary protein-to-creatinine
ratio ⬎339 mg/mmole] at baseline, or ⬍1.0 gm/gm [113
mg/mmole] if non-nephrotic [urinary protein-to-creatinine ratio ⱕ339 mg/mmole] at baseline). Renal response excluded
assessment of urinary sediment. The proportion of patients
with renal response (assessed on day 337 and confirmed on day
365 [week 52]) was evaluated. The second exploratory outcome measure was the proportion of patients achieving patient
response (assessed on day 337 and confirmed on day 365 [week
52]); this end point was in alignment with the recently released
US Food and Drug Administration guidance document for LN
(24). Patient response had 3 mutually exclusive categories:
complete patient response, partial patient response, and no
response. The criteria for complete patient response included
normal serum creatinine level, urinary protein-to-creatinine
ratio ⬍0.5 gm/gm (56.5 mg/mmole), and inactive urinary
sediment. For partial patient response, the criteria included
serum creatinine level normal or ⱕ125% of baseline, urinary
protein-to-creatinine ratio ⬍50% of baseline and ⬍3.0 gm/gm
if nephrotic at baseline or ⬍1.0 gm/gm (113 mg/mmole) if
non-nephrotic at baseline, and inactive urinary sediment or
⬎50% reduction in RBCs/hpf from baseline.
Subgroup analyses. Differences between treatment
groups, subclassified by prior treatment status (naive, recent,
inadequate response) and race (Asian versus non-Asian), in
the proportion of patients in whom confirmed complete response was achieved at week 52 were analyzed. Data were
summarized only for subgroups consisting of 10% or more of
the total study population. As a post hoc analysis, the proportion of patients in whom complete response had been achieved
at week 52 (not confirmed) was also analyzed by race (Asian
versus non-Asian). In a separate post hoc subgroup analysis,
change in proteinuria over time among patients with versus
those without nephrotic-range proteinuria at baseline was
examined.
Biomarker analyses. Pharmacodynamic variables were
also examined. Anti-dsDNA antibody and serum complement
C3 and C4 levels were determined from blood samples obtained on days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253,
281, 309, 337, and 365, or at the time of early discontinuation.
Adverse events. Adverse events (AEs), monitored
throughout the study, were defined as any new or worsening
illness, sign, symptom, or clinically significant laboratory abnormality, regardless of attribution by the investigator. A
serious AE (SAE) was defined as an AE that met any of the
following criteria: fatal, life-threatening, cancer, patient hospitalization, persistent or significant disability or incapacity,
congenital anomaly/birth defect, or an important medical
event.
Statistical analysis. A 1:1:1 randomized sample size
yielding ⬃100 patients per treatment arm provided 90% power
to detect a difference in the time to achievement of confirmed
complete response if there was an absolute difference of 20%
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Table 1. Baseline characteristics of the lupus nephritis patients and patient disposition during the study*
Variable†
Age, mean ⫾ SD years
Female
Geographic region‡
North America
South America
Europe
Rest of world
Race§
Asian
White
Black/African American
Other
Class IV glomerulonephritis
Duration of current flare, median (range) months (n ⫽ 99, 99, 96)
Baseline creatinine, median (range) mg/dl
Baseline UPCR, mg/mmole (n ⫽ 99, 99, 99)
Mean ⫾ SD
Median (range)
Baseline UPCR ⬎3 gm/gm (339 mg/mmole)
Prestudy treatment status
Naive (no treatment for current flare)
Recent treatment (ⱕ3 months MMF/GCs)
Inadequate response (⬎3 months MMF/GCs)
Baseline prednisone or oral prednisone equivalent daily dose,
mean ⫾ SD mg (n ⫽ 98, 99, 99)
Concomitant treatment with ACE inhibitors/angiotensin
receptor blockers
Premature discontinuation
Death
Adverse event
Lack of efficacy
Withdrew consent
No longer met study criteria
Poor compliance/noncompliance
Pregnancy

Abatacept 30/10
(n ⫽ 99)

Abatacept 10/10
(n ⫽ 99)

Placebo
(n ⫽ 100)

31.0 ⫾ 9.5
84 (84.8)

30.5 ⫾ 10.6
86 (86.9)

31.8 ⫾ 9.0
81 (81.0)

12 (12.1)
15 (15.2)
9 (9.1)
63 (63.6)

9 (9.1)
19 (19.2)
21 (21.2)
50 (50.5)

13 (13.0)
18 (18.0)
16 (16.0)
53 (53.0)

60 (60.6)
28 (28.3)
6 (6.1)
5 (5.1)
76 (76.8)
1.0 (0–143)
0.9 (0.4–2.7)

49 (49.5)
45 (45.5)
3 (3.0)
2 (2.0)
76 (76.8)
1.0 (0–49)
0.8 (0.4–2.5)

55 (55.0)
38 (38.0)
5 (5.0)
2 (2.0)
68 (68.0)
1.0 (0–36)
0.8 (0.5–2.0)

445.7 ⫾ 380.8
339 (57–2,458)
39 (39.4)

482.8 ⫾ 953.8
285 (50–9,400)
38 (38.4)

403.1 ⫾ 329.4
312 (14–1,668)
45 (45.0)

12 (12.1)
51 (51.5)
36 (36.4)
39.5 ⫾ 18.6

12 (12.1)
51 (51.5)
36 (36.4)
41.6 ⫾ 14.1

12 (12.0)
51 (51.0)
37 (37.0)
43.1 ⫾ 17.6

48 (48.5)

42 (42.4)

49 (49.0)

23 (23.2)
1 (1.0)
15 (15.2)
5 (5.1)
1 (1.0)
1 (1.0)
0
0

25 (25.3)
1 (1.0)
13 (13.1)
6 (6.1)
1 (1.0)
1 (1.0)
1 (1.0)
2 (2.0)

22 (22.0)
5 (5.0)
9 (9.0)
4 (4.0)
2 (2.0)
2 (2.0)
0
0

* No formal statistical comparisons were made for the 2 abatacept treatment groups versus placebo. Except where indicated otherwise,
values are the number (%). UPCR ⫽ urinary protein-to-creatinine ratio; MMF ⫽ mycophenolate mofetil; GCs ⫽ glucocorticoids;
ACE ⫽ angiotensin-converting enzyme.
† For variables with missing data in 1 or more of the groups, n values in the abatacept 30/10, abatacept 10/10, and placebo groups,
respectively, are specified.
‡ Mexico was included among the South American sites. Rest of world includes Asia; the majority of the rest-of-world patients were
in China and India.
§ Race was self-identified; therefore, patients of Hispanic descent may have identified as white, black/African American, or other.

in response rates between an abatacept regimen and placebo at
a significance level of 0.05. This power estimate, based on the
log rank test, assumed a background confirmed complete
response rate of 20%, a response rate of 40% in the abatacept
treatment group, and a constant hazard ratio. The testing of
the 2 abatacept dose regimens for the primary measurement of
the time to confirmed complete response was performed using
the Hochberg multiple testing procedure in order to maintain
the overall type I error rate at ⱕ5%. Only the primary efficacy
end point was formally tested for statistical significance; descriptive statistics are provided for all subsequent analyses. The
proportion of patients with confirmed complete response at
week 52 was assessed using sequential testing in a hierarchical
manner within each treatment group, and assessment of all

other secondary efficacy end points was performed in a
nonhierarchical manner without correction for multiplicity.
All efficacy analyses were based on the intent-to-treat
population, defined as all randomized patients for whom study
medication data on the electronic case report form indicated
that at least 1 infusion of study medication was administered.
The primary efficacy end point was analyzed using a Cox
proportional hazards model with randomization strata and
treatment group as covariates. The exploratory variable of
patient response at week 52 was analyzed with a cumulative
logit model that included treatment group and randomization
strata as covariates. Point estimates and 95% confidence
intervals (95% CIs) for differences in proportions between
each abatacept treatment group and placebo for all other
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A
100
Cumulative proportion of
patients (%)

secondary prespecified and exploratory efficacy end points
were computed using the minimum risk weights method to
account for randomization strata. All safety analyses were
based on the all-treated analysis population, which included all
patients who had received at least 1 infusion of study medication during the double-blind treatment period.
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80
60
40
20
0
0

Number at risk
1
Visit day
Abatacept 30/10 99
Abatacept 10/10 99
100
Placebo

29

57

85 113 141 169 197 225 253 281 309 337 365 393

29
98
96
98

57
95
95
98

85
94
89
92

Days
113 141 169 197 225 253 281 309 337 365 393
1
91 86 80 75 73 68 66 62 59 53
1
82 75 74 72 70 63 60 56 52 45
0
89 83 80 77 75 71 68 66 63 55

B
100
Cumulative proportion of
patients (%)

Patient disposition and baseline characteristics.
Of the 423 patients screened for the study, 300 were
randomized and 298 were treated (1 died prior to
treatment; 1 discontinued due to deviation from enrollment criteria). Demographic and baseline disease characteristics were well balanced across treatment groups
(Table 1), with the following exceptions: fewer patients
randomized to the placebo group had class IV disease,
and the placebo group exhibited a lower mean urinary
protein-to-creatinine ratio and a narrower range of
urinary protein-to-creatinine ratio values compared with
the abatacept-treated groups.
The numbers of patients who prematurely discontinued study participation during the 12-month treatment period were similar across groups: 23 (23.2%), 25
(25.3%), and 22 (22.0%) in the abatacept 30/10, abatacept 10/10, and placebo groups, respectively. Reasons for
premature discontinuation are summarized in Table 1.
Efficacy end points. The primary end point, time
to achievement of a confirmed complete response, was
not met. Confirmed complete response was achieved in
few patients at any time during treatment (22.2%,
27.3%, and 20.0% in the abatacept 30/10, abatacept
10/10, and placebo groups, respectively), and the time to
confirmed response was not statistically significantly
different across treatment arms (Figure 1A). The time to
achievement of partial response (based on renal improvement) was also similar among treatment groups
(Figure 1B).
The proportions of patients who met the criteria
for confirmed complete response at week 52 were
similar across treatment groups (9.1%, 11.1%, and 8.0%
in the abatacept 30/10, abatacept 10/10, and placebo
groups, respectively) (Table 2). Renal improvement
response rates at week 52 were higher in the abatacept
30/10 group (38.4%) and the abatacept 10/10 group
(37.4%) compared with the placebo group (31.0%)
(Table 2). The point estimates for the absolute differences in renal improvement between the abatacept
groups and the placebo group were 8.3 (95% CI –5.1,
21.7) for abatacept 30/10 and 7.3 (95% CI –6.1, 20.7) for
abatacept 10/10. Other secondary efficacy end points
(durability of complete response, mean change from

Abatacept 30/10 mg/kg
Abatacept 10/10 mg/kg
Placebo

Abatacept 30/10 mg/kg
Abatacept 10/10 mg/kg
Placebo

80
60
40
20
0

Number at risk
Visit day
Abatacept 30/10
Abatacept 10/10
Placebo

0

29 57

1
99
99
100

29
89
87
90

85 113 141 169 197 225 253 281 309 337 365 393

Days
57
70
81
82

85
62
65
69

113 141 169 197 225 253 281 309 337 365 393
0
53 48 35 27 20 17 14 12 12 11
0
49 40 35 30 24 22 19 14 14 11
0
58 46 42 37 30 28 25 23 22 20

Figure 1. A, Time to achievement of confirmed complete response, by
treatment group. B, Time to achievement of renal improvement, by
treatment group. No formal statistical comparisons were made for the
analysis of time to achievement of renal improvement.

baseline in renal function, mean change from baseline in
SDI, SF-36, Fatigue VAS, and FSS scores) consistently
showed no differences between the abatacept and placebo groups (see Supplementary Table 3, available on
the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.38260/abstract).
Due to the stringent nature of the confirmed
complete response end point, few patients met the
criteria at any time point, and minor fluctuations in
eGFR led to variations in the numbers of patients
classified as having achieved confirmed complete re-
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Table 2. Percentage of patients with responses at week 52*
End point
Prespecified end points
Complete clinical response at week 52, no. (%) [95% CI]†
Renal improvement at week 52, no. (%) [95% CI]‡
Additional renal end points
Patient response at week 52
Patients with response, no. (%) [95% CI]
Complete response, no. (%)§
Partial response, no. (%)¶
No response, no. (%)
Renal response at week 52, no. (%) [95% CI]#
Prespecified subanalyses
Complete clinical response at week 52 by prior treatment status,
no. with response/no. analyzed (%) [95% CI]**
Naive
Recent
Inadequate response
Complete clinical response at week 52 by race, no. with
response/no. analyzed (%)**
Asian
Non-Asian
Post hoc subanalysis
Complete clinical response at week 52 by race, no. with
response/no. analyzed (%)††
Asian
Non-Asian

Abatacept 30/10
(n ⫽ 99)

Abatacept 10/10
(n ⫽ 99)

Placebo
(n ⫽ 100)

9 (9.1)
[3.4, 14.8]
38 (38.4)
[28.8, 48.0]

11 (11.1)
[4.9, 17.3]
37 (37.4)
[27.8, 46.9]

8 (8.0)
[2.7, 13.3]
31 (31.0)
[21.9, 40.1]

38 (38.4)
[28.8, 48.0]
24 (24.2)
14 (14.1)
61 (61.6)
45 (45.5)
[35.6, 55.3]

30 (30.3)
[21.3, 39.4]
21 (21.2)
9 (9.1)
69 (69.7)
39 (39.4)
[29.8, 49.0]

34 (34.0)
[24.7, 43.3]
20 (20.0)
14 (14.0)
66 (66.0)
33 (33.0)
[23.8, 42.2]

1/12 (8.3)
[0.2, 38.5]
6/51 (11.8)
[2.9, 20.6]
2/36 (5.6)
[0.7, 18.7]

2/12 (16.7)
[2.1, 48.4]
7/51 (13.7)
[4.3, 23.2]
2/36 (5.6)
[0.7, 18.7]

3/12 (25.0)
[5.5, 57.2]
5/51 (9.8)
[1.6, 18.0]
0/37 (0)
–

9/60 (15.0)
0/39 (0)

6/49 (12.2)
5/50 (10.0)

6/55 (10.9)
2/45 (4.4)

13/60 (21.7)
2/39 (5.1)

12/49 (24.5)
10/50 (20.0)

8/55 (14.5)
4/45 (8.9)

* No formal statistical comparisons were made for the 2 abatacept treatment groups versus placebo. 95% CI ⫽ 95% confidence
interval.
† Defined as follows: for renal function, if normal at screening, estimated glomerular filtration rate (eGFR) ⱖ90% of screening
value and if abnormal at screening, ⱖ90% of 6-month, pre-flare value; urinary protein-to-creatinine ratio (UPCR) ⬍0.26
gm/gm (30 mg/mmole); inactive urinary sediment; for confirmation, assessed on day 337 and confirmed on day 365 (week 52).
‡ Defined as follows: for renal function, if normal or 60–89 ml/minute/1.73m2 at screening, eGFR ⱖ90% of screening value and
if 15–59 ml/minute/1.73 m2, ⱖ50% improvement or ⱖ90% of 6-month, pre-flare value; UPCR ⱖ50% improvement over
screening value if abnormal at screening; inactive urinary sediment; confirmation not required.
§ Defined as follows: for renal function, serum creatinine level normal; UPCR ⬍0.5 gm/gm (56.5 mg/mole); inactive urinary
sediment; for confirmation, assessed on day 337 and confirmed on day 365.
¶ Defined as follows: for renal function, serum creatinine level normal or ⱕ125% of baseline; UPCR ⬍50% of baseline and
⬍3.0 gm/gm (339 mg/mmole) if nephrotic, or ⬍1.0 gm/gm (133 mg/mmole) if non-nephrotic; urinary sediment inactive or
⬎50% reduction in red blood cells/high-power field from baseline; for confirmation, assessed on day 337 and confirmed on day
365.
# Defined as follows: for renal function, serum creatinine level normal or ⱕ125% of baseline; UPCR ⬍50% of baseline and
⬍3.0 gm/gm if nephrotic, or ⬍1.0 gm/gm if non-nephrotic; urinary sediment not included in definition; for confirmation,
assessed on day 337 and confirmed on day 365.
** Same definition as for the prespecified end point of complete clinical response at week 52.
†† Same definition as for the prespecified end point of complete clinical response at week 52, except confirmation not required.

sponse or renal improvement. Therefore, two less stringent definitions of outcome were proposed and assessed
as exploratory measures. The respective proportions of
patients with complete, partial, or no response were
similar across groups (24.2%, 14.1%, and 61.6% in the
abatacept 30/10 group; 21.2%, 9.1%, and 69.7% in the
abatacept 10/10 group; and 20.0%, 14.0%, and 66.0% in

the placebo group). Because minor fluctuations in urinary sediment can confound interpretation, a definition
of response without urinalysis (renal response) was also
assessed. Similar to the results obtained using the definition of renal improvement, renal response was
achieved in fewer patients in the placebo group at week
52 (45.5% in the abatacept 30/10 group, 39.4% in the
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Days
A

0

29

57

85 113 141 169 197 225 253 281 309 337 365

Median change from
baseline (%)

0

Abatacept 30/10 mg/kg
Abatacept 10/10 mg/kg
Placebo

–20
–40
–60
–80

–100
Number of patients assessed at each visit day
15 29 57 85 113 141 169 197 225 253 281 309 337 365
Visit day
Abatacept 30/10
38 38 38 32 35 34 33 33 31 30 31 29 29 30
Abatacept 10/10
34 36 31 33 30 31 30 30 30 27 27 26 26 25
Placebo
43 44 42 41 41 40 37 37 36 34 34 34 34 33

Days
B

0

0
Median change from
baseline (%)

abatacept 10/10 group, and 33.0% in the placebo group)
(Table 2). Estimates of the treatment differences in
renal response relative to placebo were 12.6% (95% CI
–1.1, 26.2) for the abatacept 30/10 group and 6.2% (95%
CI –7.1, 19.4) for the abatacept 10/10 group.
Subanalyses of patients stratified according to
prior treatment, race, and baseline nephrotic-range
proteinuria. Patients were stratified at randomization
according to variables in background therapy (naive,
recent, inadequate response), and achievement of a
prespecified efficacy end point, i.e., the percentage of
patients with confirmed complete response at week 52,
was performed. The analysis revealed no significant
differences among the treatment groups in achievement
of the efficacy end point (Table 2).
Subgroup analysis of confirmed complete response at week 52 by race (Asian versus non-Asian) also
showed no significant differences among treatment
groups (Table 2). In all treatment groups, response rates
were higher among Asian patients compared with nonAsian patients. Similar results were observed in a post
hoc subgroup analysis, by race, of the proportion of
patients in whom complete response (unconfirmed) had
been achieved at week 52. Due to the small number of
enrolled patients of African descent, separate subanalyses could not be performed for this group.
In a subgroup analysis of patients with nephroticrange proteinuria at baseline (urinary protein-tocreatinine ratio ⬎339 mg/mmole) (n ⫽ 122), there was
an ⬃20–30% greater reduction in the mean urinary
protein-to-creatinine ratio among those randomized to
receive abatacept versus placebo (Figure 2A). This
difference first became evident at week 24 and was
maintained through week 52. In contrast, among patients who did not have nephrotic-range proteinuria at
baseline, reduction in the urinary protein-to-creatinine
ratio over time was comparable across treatment groups
(Figure 2B).
Anti-dsDNA and complement levels. Greater improvements from baseline in anti-dsDNA antibody levels and complement C3 and C4 levels were seen in both
abatacept groups compared with placebo. In the abatacept groups, decreases in mean anti-dsDNA antibody
levels were achieved during the induction period (days
0–28) and maintained during the glucocorticoid taper
(after day 28) (Figure 3A). The proportion of patients
with a shift in the C3 or C4 level from low (below the
LLN) at baseline to above the LLN with treatment was
higher in both abatacept groups than in the placebo
group. For C3, this difference was apparent as early as
day 29 and persisted through day 365 (Figure 3B). The
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–20

29

57

85 113 141 169 197 225 253 281 309 337 365
Abatacept 30/10 mg/kg
Abatacept 10/10 mg/kg
Placebo

–40
–60
–80

–100
Number of patients assessed at each visit day
Visit day
15 29 57 85 113 141 169 197 225 253 281
Abatacept 30/10
60 59 57 57 57 55 51 51 52 49 45
Abatacept 10/10
58 59 56 59 53 52 53 52 51 49 51
Placebo
53 53 54 52 51 51 48 48 48 46 45

309
47
49
45

337 365
44
45
47
49
46
45

Figure 2. A, Median change from baseline in the mean urinary
protein-to-creatinine ratio among patients who had nephrotic-range
proteinuria at baseline, by treatment group. B, Median change from
baseline in the mean urinary protein-to-creatinine ratio among patients who did not have nephrotic-range proteinuria at baseline, by
treatment group. No formal statistical comparisons were made for
these subgroup analyses.

difference between the abatacept groups and the placebo group in the proportion of patients with a change in
the C4 level from below the LLN at baseline to above
the LLN with treatment became apparent on day 57 and
persisted through day 365 (Figure 3C).
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Visit day

A

0

15 29 57 85 113 141 169 197 225 253 281 309 337 365

0
Mean change from
baseline (%)

–10

Abatacept (n=198)
Placebo (n=100)

–20
–30
–40
–50
–60
–70
–80
–90

Number of patients assessed at each visit day
Visit day
15 29 57 85 113 141 169 197 225 253 281 309 337 365
179 183 176 173 167 159 158 155 154 145 148 143 139 138
Abatacept, n
90 89 90 87 83 84 77 80 77 76 72 68 73 68
Placebo, n

B
50

Patients
(%)

40
30
20
10
0
0

15 29 57

85 113 141 169 197 225 253 281 309 337 365

Visit day
Number of patients assessed at each visit day
15 29 57 85 113 141 169 197 225 253 281 309 337 365
Visit day
Abatacept, n
162 168 157 158 150 147 144 141 143 134 130 127 124 126
Placebo, n
84 84 82 80 77 75 71 72 69 67 64 65 67 64

regardless of attribution to study drug, were reported at
comparable frequencies in the abatacept and placebo
treatment groups. Table 3 shows the number of discontinuations due to AEs considered by the investigator to
be at least possibly related to the study drug.
Fourteen patients died during the double-blind
treatment period (5 [5.1%], 2 [2.0%], and 7 [7.0%] in the
abatacept 30/10, abatacept 10/10, and placebo groups,
respectively). In 5 patients (3 placebo-treated, 2 abatacept 30/10–treated), the cause of death was ascribed to
their underlying disease (acute renal failure, worsening
SLE, and multiple organ failure, respectively, in the 3
placebo-treated patients; multiple organ failure in each
of the 2 abatacept 30/10–treated patients). Seven deaths
were related to infection (bronchopneumonia, sepsis,
malaria, pneumonia [accompanied by cardiac failure],
respectively, in 4 patients in the placebo group;
pneumonia/lung abscess and bacterial peritonitis, respectively, in 2 patients in the abatacept 30/10 group,
and interstitial pneumonia in 1 patient in the abatacept
10/10 group).
The proportions of patients with SAEs were
similar among the 3 treatment groups (Table 3), with
infections being the most commonly reported events.
Pneumonia was the most common serious infection, and
was reported in a similar percentage of patients in each
group. Herpes zoster occurred at higher rates in both

C
60

Table 3.

Patients
(%)

50

Summary of adverse events (AEs)*
Abatacept Abatacept
30/10
10/10
Placebo
(n ⫽ 99) (n ⫽ 99) (n ⫽ 100)

40
30
20
10
0
0

15 29 57 85 113 141 169 197 225 253 281 309 337 365

Visit day
Number of patients assessed at each visit day
15 29 57 85 113 141 169 197 225 253 281 309 337 365
Visit day
126 129 119 119 117 116 116 112 114 107 105 101 100 99
Abatacept, n
73 73 70 69 67 65 62 64 61 60 58 57 59 57
Placebo, n

Figure 3. Biomarker levels through week 52. A, Changes in anti–
double-stranded DNA antibody levels from baseline, as assessed by
enzyme-linked immunosorbent assay. B, Percentage of patients with
low complement C3 levels at baseline whose C3 levels normalized. C,
Percentage of patients with low complement C4 levels at baseline
whose C4 levels normalized. No formal statistical comparisons were
made for the biomarker analyses.

Safety. Safety findings were similar with abatacept 30/10, abatacept 10/10, and placebo (Table 3). AEs,

All AEs
Related AEs
Discontinued due to AEs†
Deaths‡
Serious AEs
Infections
Pneumonia
Herpes zoster
Gastroenteritis
Urinary tract infection
Renal failure§
Related serious AEs
Discontinued due to serious AEs
Peri-infusional AEs
Acute infusional AEs

93 (93.9)
61 (61.6)
14 (14.1)
5 (5.1)
33 (33.3)
23 (23.2)
4 (4.0)
3 (3.0)
5 (5.1)
0
3 (3.0)
20 (20.2)
14 (14.1)
23 (23.2)
4 (4.0)

89 (89.9)
53 (53.5)
13 (13.1)
2 (2.0)
28 (28.3)
18 (18.2)
4 (4.0)
6 (6.1)
1 (1.0)
2 (2.0)
2 (2.0)
19 (19.2)
12 (12.1)
18 (18.2)
4 (4.0)

94 (94.0)
55 (55.0)
9 (9.0)
7 (7.0)
31 (31.0)
17 (17.0)
3 (3.0)
0
2 (2.0)
2 (2.0)
3 (3.0)
15 (15.0)
7 (7.0)
17 (17.0)
3 (3.0)

* No formal statistical comparisons were made for the 2 abatacept
treatment groups versus placebo. Values are the number (%).
† According to the Action Taken Regarding Study Drug field on the
Adverse Event Case Report form.
‡ All deaths reported during the double-blind period, including those
that occurred ⬎56 days after the last dose of study treatment.
§ Includes acute and chronic renal failure.
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abatacept-treated groups compared with the placebo
group, and rates of gastroenteritis were highest in the
abatacept 30/10 group. SAEs considered by the investigator to be at least possibly related to the study drug
were more frequent in the abatacept groups; of these,
“infections and infestations” were the most common
(18.2%, 15.2%, and 12.0% in the abatacept 30/10,
abatacept 10/10, and placebo groups, respectively).
Rates of study discontinuation due to SAEs were also
higher in the abatacept groups compared with the
placebo group (Table 3).
Prespecified and prospectively defined periinfusional AEs (reported within 24 hours after the start
of study medication infusion) were reported in similar
numbers of patients in all treatment groups (Table 3).
Two peri-infusional events were serious (1 in a patient
receiving abatacept 30/10; 1 in a patient receiving placebo), but none resulted in study discontinuation. Acute
infusional AEs—a subset of peri-infusional AEs defined
as those occurring within 1 hour of infusion—were
reported in a small percentage of patients in each group.
None of the acute infusional AEs was serious or resulted
in discontinuation of study medication.
DISCUSSION
Treatment of active LN includes high-dose glucocorticoids, together with prolonged treatment with
immunosuppressants. Deaths and treatment failures are
common in the first year of therapy, and complete
response is often delayed or not achieved (25–29).
Several agents have been investigated as add-on therapies for LN. In the Lupus Nephritis Assessment with
Rituximab (LUNAR) study (ClinicalTrials.gov identifier
NCT00282347), rituximab failed to demonstrate additional efficacy, and the ocrelizumab and atacicept programs were prematurely terminated because of toxicity
(30–32).
The rationale for considering abatacept for the
treatment of LN included not only preclinical evidence
that CTLA-4Ig is effective in treating and preventing
nephritis in the NZB ⫻ NZW mouse model (5–7), but
also observations in a study of extrarenal lupus indicating favorable effects on anti-dsDNA antibody levels (9).
The consistent safety profile of abatacept in combination with immunosuppressants in patients with RA
(33–35) or SLE (9) provided additional support for
investigations of abatacept as combination treatment in
LN.
The present study is the first randomized,
placebo-controlled trial of the efficacy and safety of IV
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abatacept added to background therapy in adult patients
with LN. Overall, the safety profile for IV abatacept in
patients with active LN was comparable to that of MMF
and glucocorticoids alone, with the exception of higher
frequencies of moderate-to-severe herpes zoster infections (grades II and III). The safety profile generated
from this study is consistent with the results of previous
studies comparing abatacept with placebo in patients
with RA (33–35).
The study did not meet its prespecified primary
efficacy end point of time to confirmed complete response. However, treatment with IV abatacept was
associated with improved levels of anti-dsDNA antibodies, complement, and urinary protein. As has also been
reported previously (17,20), a post hoc review indicated
several limitations relevant to the present study that may
have obscured treatment effects measured using the
primary end point and some secondary end points.
These include the disproportionate allocation of patients with lower levels of urinary protein in the placebo
arm, unrestricted use of glucocorticoids during the treatment period, and a stringent definition of confirmed
complete response that may have failed to capture some
clinically and prognostically significant end points.
The definition of confirmed complete response,
which required that the eGFR was ⱖ90% of the reference value (confirmed at 2 time points), led to the
exclusion of patients experiencing minor fluctuations in
creatinine levels and reduced the confirmed complete
response rates in all groups (to 8.0–11.1%—levels far
lower than those observed in other clinical trials)
(25,31). For example, in the LUNAR study, the definition of complete response required a serum creatinine
level within 15% of the baseline level and did not require
confirmation of response on a consecutive visit. Although the primary end point was not met in that trial,
the proportion of patients achieving the trial-specified
definition of complete response in the LUNAR study
ranged from 26.4% to 30.6% (31).
Noting the variation among primary end points in
LN trials, Wofsy et al (19) explored the impact of
different definitions of a complete response end point
on the results in subsets of patients from the present
data set. The analysis considered only patients who met
the entry criteria for the given trial whose end point
criteria were being applied, and required a successful
taper of glucocorticoids to ⱕ10 mg/day for the patient to
be considered to show response. The week 52 complete
response rates were as follows for the abatacept 30/10,
abatacept 10/10, and placebo groups, respectively: ACRrecommended end point 13.0%, 14.0%, and 6.0%;
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LUNAR trial end point 24.0%, 22.0%, and 6.0%;
Aspreva Lupus Management Study (ClinicalTrials.gov
identifier NCT00377637) end point 28.0%, 25.0%, and
13.0%, and the end point being used in the Abatacept
and Cyclophosphamide Combination: Efficacy and
Safety Study (an ongoing National Institutes of Health–
sponsored trial; ClinicalTrials.gov identifier
NCT00774852) 33.0%, 36.0%, and 19.0%. In this exploratory analysis, the choice of primary efficacy measure
had substantial impact on the results of the current study
(19,20), demonstrating that the stringent definition of
confirmed complete response used in the present study
was the least discriminating among end points tested.
Study end points may also have been affected by
use of glucocorticoids. Although it was recommended in
the protocol that glucocorticoids be tapered over a
12-week period, glucocorticoid administration, including
by IV pulse, was permitted throughout the study period
for safety reasons. The proportion of patients receiving
IV pulse glucocorticoids was similar across treatment
arms (44.4%, 44.4%, and 45.0% in the abatacept 30/10,
abatacept 10/10, and placebo groups, respectively); however, the proportion receiving pulse glucocorticoids after
the first 3 months differed across groups (17.2%, 9.1%,
and 18.0%, respectively). Confirmed complete response
was achieved in few patients who were treated with pulse
glucocorticoids (4.0%, 5.0%, and 3.0%, respectively).
Thus, although the imbalance may not have affected
confirmed complete response substantially, pulse glucocorticoids could have had an impact on partial responses
and other estimates of response. Therefore, in future
clinical studies, background use of glucocorticoids
should be carefully controlled.
Findings of the present study illustrate the importance of applying appropriate end points in LN trials. In
patients with active class III or IV LN who were
receiving background MMF and glucocorticoids, treatment with IV abatacept was associated with an acceptable safety profile and with improvement in anti-dsDNA
antibody levels and complement levels. In those with
nephrotic-range proteinuria at baseline, greater reductions in proteinuria were observed in the abatacept
treatment groups than in the placebo group. Although
the primary efficacy end point was not met, the findings
of the exploratory and post hoc analyses support further
evaluation of abatacept for the treatment of LN.
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